Carbohydrate Microarray Profiling of Glycan-Binding Antibodies and Lectins

碳水化合物结合抗体广泛用于基础研究，并可用作诊断和治疗剂。它们在癌症领域特别有用。癌细胞在疾病的发作和进展期间经历碳水化合物表达的急剧变化。因此，人们对理解为什么会发生这些变化、它们如何导致疾病以及将这些变化用于临床用途产生了相当大的兴趣。例如，Unituxin（dinituximab）是FDA批准的单克隆抗体，其靶向肿瘤相关的碳水化合物GD 2并用于治疗患有神经母细胞瘤的儿童。不幸的是，很少有针对碳水化合物的良好单克隆抗体。缺乏高质量的抗体是该领域的主要障碍。我们正采取多管齐下的方法，协助纾缓这个问题。首先，我们使用我们的聚糖微阵列来评估现有抗体对碳水化合物的选择性。这些信息对于为特定应用选择正确的抗体和解释结果至关重要。其次，我们开发了一个碳水化合物抗体数据库（抗聚糖试剂数据库; DAGR），可用于查找抗体和有关这些抗体的信息。第三，我们正在研究哺乳动物产生碳水化合物抗体的机制。第四，我们正在使用我们的聚糖微阵列来发现和设计针对碳水化合物的新抗体

Carbohydrate-binding antibodies are used extensively for basic research and are useful as diagnostic and therapeutic agents. They are especially useful in the field of cancer. Cancer cells undergo dramatic changes in carbohydrate expression during the onset and progression of disease. As a result, there has been considerable interest in understanding why these changes occur, how they contribute to the disease, and exploiting these changes for clinical use. For example, Unituxin (dinituximab) is an FDA approved monoclonal antibody that targets the tumor associated carbohydrate GD2 and is used to treat children with neuroblastoma. Unfortunately, there are very few good monoclonal antibodies to carbohydrates. The lack of high quality antibodies is a major barrier for the field. We are taking a multi-pronged approach to help alleviate this problem. First, we use our glycan microarray to evaluate the selectivities of existing antibodies to carbohydrates. This information is crucial for selecting the right antibody for a particular application and interpreting results. Second, we have developed a database of antibodies to carbohydrates (Database of Anti-Glycan Reagents; DAGR) that can be used to find antibodies and information about those antibodies. Third, we are studying the mechanisms by which antibodies to carbohydrates are produced in mammals. Fourth, we are using our glycan microarray to discover and engineer new antibodies to carbohydrates